Edwards Lifesciences (EW) Revenue (2009 - 2026)

Edwards Lifesciences' Revenue history runs 18 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• On a quarterly basis, Revenue rose 16.7% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $6.3 billion, a 14.15% increase from a year earlier, with the FY2025 full-year figure at $6.1 billion, up 11.55% from the prior year.
• Revenue rose to $1.6 billion in Q1 2026 per EW's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Revenue topped out at $1.6 billion in Q1 2026 and bottomed at $429.9 million in Q4 2022.
• The 5-year median for Revenue is $1.4 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Revenue plunged 67.67% in 2022 and soared 194.58% in 2023, its largest moves.
• Year by year, Revenue stood at $429.9 million in 2022, then surged by 194.58% to $1.3 billion in 2023, then climbed by 9.43% to $1.4 billion in 2024, then gained by 13.26% to $1.6 billion in 2025, then increased by 5.03% to $1.6 billion in 2026.
• Per Business Quant, the three latest EW Revenue figures stand at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025).